TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19583932

Group type: EXPERIMENTAL
Intervention: Chinese compound herbal medicine for reinforcing qi, activating blood circulation, expelling phlegm and dredging collaterals + simvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 60
Study: 17081270

Group type: EXPERIMENTAL
Intervention: Efalizumab (1.0 mg/kg/week for 12 weeks)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Efalizumab re-treatment after relapse
Number of subjects: 308

Group type: COMPARATOR
Intervention: Efalizumab (initial treatment)
Number of subjects: 308
Study: 15646475

Group type: EXPERIMENTAL
Intervention: 30% or greater pressure reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors (gender, ethnic background, migraine, disc hemorrhage)
Number of subjects: 0
Study: 11705718

Group type: EXPERIMENTAL
Intervention: Psychomotor processing speed
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reaction time measures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPT assessments
Number of subjects: 60
Study: 9231452

Group type: EXPERIMENTAL
Intervention: Drinking and Driving Component
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responsible beverage service policies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local ordinances and regulations
Number of subjects: 0
Study: 8180400

Group type: EXPERIMENTAL
Intervention: Filtered red blood cells and platelets
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard red blood cells and platelets (nonfilter)
Number of subjects: 123
Study: 31527020

Group type: EXPERIMENTAL
Intervention: MTBDRplus group (discontinuation of ethambutol based on MTBDRplus assay results)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Guideline group (discontinuation of ethambutol based on phenotypic drug susceptibility test)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MTBDRplus group
Number of subjects: 600

Group type: COMPARATOR
Intervention: Guideline group
Number of subjects: 600
Study: 30222081

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine and cerium nitrate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 27043785

Group type: EXPERIMENTAL
Intervention: Hypnosis (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 44
Study: 25381076

Group type: EXPERIMENTAL
Intervention: Nurse navigation (navigation)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 147
Study: 22836050

Group type: EXPERIMENTAL
Intervention: 64 Gy in 32 fractions over 6.4 weeks RT schedule
Number of subjects: 34

Group type: COMPARATOR
Intervention: 55 Gy in 20 fractions over 4 weeks RT schedule
Number of subjects: 34
Study: 19916101

Group type: EXPERIMENTAL
Intervention: Asymptomatic HD carriers
Number of subjects: 105

Group type: COMPARATOR
Intervention: Noncarriers
Number of subjects: 105
Study: 18383967

Group type: EXPERIMENTAL
Intervention: Sevo-N2O group inhaled 8% sevoflurane in a 60/40% mixture of oxygen and N2O
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sevo-air group received 8% sevoflurane in a mixture of oxygen and air (inspired oxygen fraction, 40%)
Number of subjects: 44
Study: 16323175

Group type: EXPERIMENTAL
Intervention: Voice therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no voice therapy)
Number of subjects: 23
Study: 12725761

Group type: EXPERIMENTAL
Intervention: fMRI (repetitive flexion-extension of the last four fingers of the right hand)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Conventional MRI scans
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: New, unlocalized proton MR spectroscopy (1HMRS) sequence to measure the concentration of N-acetylaspartate of the whole brain (WBNAA)
Number of subjects: 16
Study: 11076818

Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 1570
Study: 8780451

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITBN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 0
Study: 1600930

Group type: EXPERIMENTAL
Intervention: Calcium (3 mg) added to meals containing iron (0.01 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Addition of milk, milkshake, or cheese to meals (pizza or hamburger)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Calcium in previous studies (higher amounts, lower molar ratio)
Number of subjects: 57
Study: 6143466

Group type: EXPERIMENTAL
Intervention: Alfentanil 7.5 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 31478126

Group type: EXPERIMENTAL
Intervention: Passive myofunctional therapy (PMFT) using an oral device nightly for 1 year
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no oral device)
Number of subjects: 57
Study: 29929533

Group type: EXPERIMENTAL
Intervention: Acetaminophen and dexmedetomidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acetaminophen and propofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexmedetomidine and placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol and placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 26178202

Group type: EXPERIMENTAL
Intervention: Decision aid website
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Computer-generated treatment preferences
Number of subjects: 101

Group type: COMPARATOR
Intervention: Survey first
Number of subjects: 101
Study: 25707085

Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 (SB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ambar (AM)
Number of subjects: 35
Study: 22344353

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (GI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hypopressive exercises (GII)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (GIII)
Number of subjects: 58
Study: 20717126

Group type: EXPERIMENTAL
Intervention: L-ornithine hydrochloride (0.1 g/kg body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17980769

Group type: EXPERIMENTAL
Intervention: Tonsillectomy with Argon Plasma Coagulation (APC)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Conventional tonsillectomy (cold dissection)
Number of subjects: 226
Study: 15842429

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12485262

Group type: EXPERIMENTAL
Intervention: Non-ionic radiographic contrast media with different osmolalities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant antithrombotic therapy (platelet aggregation inhibitors and heparins)
Number of subjects: 0
Study: 9660243

Group type: EXPERIMENTAL
Intervention: Oral food challenge
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (patients with negative food challenge)
Number of subjects: 31
Study: 7659391

Group type: EXPERIMENTAL
Intervention: Cortical peel (CP) image analysis using cylindrical transformation of HMPAO SPET data
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cortical peel (CP) image analysis
Number of subjects: 30
Study: 2652199

Group type: EXPERIMENTAL
Intervention: Conservative management (tumorectomy and breast irradiation)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 179
Study: 919112

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study: 30902687

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound (US)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Manual palpation (MP)
Number of subjects: 111
Study: 27926769

Group type: EXPERIMENTAL
Intervention: ACE inhibitor therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients with MF
Number of subjects: 76
Study: 26030651

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/day for 12 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 24002794

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control
Number of subjects: 270
Study: 20629937

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise for 12 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 66
Study: 18848382

Group type: EXPERIMENTAL
Intervention: Radical nephrectomy with complete lymph-node dissection
Number of subjects: 772

Group type: COMPARATOR
Intervention: Radical nephrectomy alone
Number of subjects: 772
Study: 16686769

Group type: EXPERIMENTAL
Intervention: New AH criteria
Number of subjects: 38

Group type: COMPARATOR
Intervention: Banff criteria
Number of subjects: 38
Study: 14600563

Group type: EXPERIMENTAL
Intervention: VG + creatine (VGCr)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NV + creatine (NVCr)
Number of subjects: 42

Group type: COMPARATOR
Intervention: VG + placebo (VGPl)
Number of subjects: 42

Group type: COMPARATOR
Intervention: NV + placebo (NVPl)
Number of subjects: 42
Study: 10984252

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at a dose of 0.6 IU/kg/day (0.2 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I) stimulated through the GH axis
Number of subjects: 0
Study: 8960082

Group type: EXPERIMENTAL
Intervention: Dobutamine with low dose dipyridamole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Dobutamine only)
Number of subjects: 10
Study: 1493717

Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 209

Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 209
Study: 3009633

Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine (MMU 18006)
Number of subjects: 23
Study: 31064405

Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Enoxaparin 20 mg
Number of subjects: 32
Study: 28332324

Group type: EXPERIMENTAL
Intervention: Starting Early intervention with individual nutrition counseling and nutrition and parenting support groups
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control group receiving standard prenatal and pediatric primary care
Number of subjects: 533
Study: 25398374

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for 28 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 28
Study: 22806415

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 60
Study: 21710170

Group type: EXPERIMENTAL
Intervention: Stress group (Trier Social Stress Task)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-stress group
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All participants after marijuana cue exposure
Number of subjects: 87
Study: 18339466

Group type: EXPERIMENTAL
Intervention: Health services quality improvement intervention
Number of subjects: 19
Study: 17120754

Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fentanyl (F)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tramadol (T)
Number of subjects: 150
Study: 12627188

Group type: EXPERIMENTAL
Intervention: Fermented milk product containing GABA (FMG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11742968

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trials (SBTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation
Number of subjects: 0
Study: 10423637

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) therapy
Number of subjects: 0
Study: 8273358

Group type: EXPERIMENTAL
Intervention: Relaxation training programs (after patient education)
Number of subjects: 49
Study: 3303944

Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin (4 gm intravenously)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Multiple-dose piperacillin (three 2 gm doses intravenously 4 hours apart)
Number of subjects: 116
Study: 30198779

Group type: EXPERIMENTAL
Intervention: Soy nut (30g/day for 12 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cowpea nut (30g/day for 12 weeks)
Number of subjects: 56
Study: 27914512

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 5mg/kg for 2 weeks, then 10mg/kg for the next 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24943065

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery for 4 weeks overnight
Number of subjects: 24

Group type: COMPARATOR
Intervention: Insulin pump therapy for 4 weeks overnight (control)
Number of subjects: 24
Study: 23452709

Group type: EXPERIMENTAL
Intervention: Open recovery room (connected to nature)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Closed recovery room (not connected to nature)
Number of subjects: 16
Study: 20890710

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS) patients during supine rest and LBNP -20 mmHg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS) patients during LBNP -20 mmHg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy control subjects during supine rest and LBNP -20 mmHg
Number of subjects: 14
Study: 18692805

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 20 mg daily (n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg daily (n = 26)
Number of subjects: 52
Study: 16813773

Group type: EXPERIMENTAL
Intervention: Functional walking (FW) exercise program
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: In balance (IB) exercise program
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 278
Study: 12773973

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal hernia repair (TEP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Open mesh technique (Lichtenstein repair)
Number of subjects: 168
Study: 10687834

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (valerate estradiol‐‐2 mg/day for 21 days and cyproterone acetate‐‐1 mg/day for 10 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9078545

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 500 U/kg/wk for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8399013

Group type: COMPARATOR
Intervention: No extra vitamins
Number of subjects: 135

Group type: COMPARATOR
Intervention: Folic acid supplementation alone
Number of subjects: 135

Group type: COMPARATOR
Intervention: Folic acid and other vitamin supplementation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Other vitamin supplementation
Number of subjects: 135
Study: 3812449

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease prevalence among persons aged 65+ years
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease prevalence among persons aged 80+ years
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Age-adjusted prevalence of Alzheimer's disease in persons aged 65+ years after correction for false negatives
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Prevalence of Alzheimer‐type senile dementia among men
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Prevalence of Alzheimer‐type senile dementia among women
Number of subjects: 817
Study: 29783268

Group type: EXPERIMENTAL
Intervention: Progestin-primed ovarian stimulation (PPOS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Short-term protocol
Number of subjects: 93
Study: 27591024

Group type: EXPERIMENTAL
Intervention: Prebiotic (Synergy 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Glucidex 29 Premium)
Number of subjects: 40
Study: 25037201

Group type: EXPERIMENTAL
Intervention: Clinical findings after return to play (RTP)
Number of subjects: 64
Study: 22883122

Group type: EXPERIMENTAL
Intervention: Human aspart insulin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 80
Study: 20836951

Group type: EXPERIMENTAL
Intervention: Smartbur
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carbide bur
Number of subjects: 24
Study: 18477490

Group type: EXPERIMENTAL
Intervention: NGM/EE (n=1506)
Number of subjects: 2563

Group type: COMPARATOR
Intervention: norethindrone acetate/EE (n=1057)
Number of subjects: 2563
Study: 21396140

Group type: EXPERIMENTAL
Intervention: 150 g of fructose/d for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 150 g of glucose/d for 4 weeks
Number of subjects: 20
Study: 16139347

Group type: EXPERIMENTAL
Intervention: Spiritually based booklet
Number of subjects: 108

Group type: COMPARATOR
Intervention: Demographically targeted booklet (secular)
Number of subjects: 108
Study: 12127050

Group type: EXPERIMENTAL
Intervention: Anthrax vaccine (specific lots containing squalene)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anthrax vaccine (general AVIP participants)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (non-vaccinated personnel)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preimmunization sera from AVIP personnel
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-vaccination sera from AVIP personnel
Number of subjects: 25
Study: 9843287

Group type: EXPERIMENTAL
Intervention: Visual cue triggering with 75 ml of contrast agent at 1.5 ml/sec
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Automated ROI threshold triggering with 75 ml of contrast agent at 1.5 ml/sec
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group with 150 ml of contrast agent at 1 ml/sec
Number of subjects: 120
Study: 8078551

Group type: EXPERIMENTAL
Intervention: Cytarabine 100 mg/m²/day for 5 days by continuous infusion
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Cytarabine 400 mg/m²/day for 5 days by continuous infusion
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Cytarabine 3 g/m² in a 3-hour infusion every 12 hours on days 1, 3, and 5
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 693
Study: 2586471

Group type: EXPERIMENTAL
Intervention: Laser irradiation (50mW)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No laser irradiation (control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Low-power laser for microvascular anastomosis
Number of subjects: 124
Study: 53506

Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 50

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 50
Study: 11515714

Group type: EXPERIMENTAL
Intervention: NIPRISAN
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 30787295

Group type: EXPERIMENTAL
Intervention: Intradermal injections of modified mRNA encoding VEGF‐A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buffered saline placebo
Number of subjects: 0
Study: 28106245

Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day) + active lifestyle intervention
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo + active lifestyle intervention
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day) alone
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 2000
Study: 26552715

Group type: EXPERIMENTAL
Intervention: Standardized weaning from CPAP
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standardized weaning from CPAP (post-intervention)
Number of subjects: 41
Study: 24122176

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1.5 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 23019830

Group type: EXPERIMENTAL
Intervention: School environment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hospital dental setup
Number of subjects: 60
Study: 20175270

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 17427914

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for chronic nightmares
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 27
Study: 16268466

Group type: EXPERIMENTAL
Intervention: Ximelagatran (24 mg twice daily)
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 1223
Study: 12619264

Group type: EXPERIMENTAL
Intervention: Chewing gum containing pyrophosphate (1%) and tripolyphosphate (1%)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 28
Study: 10347985

Group type: EXPERIMENTAL
Intervention: 160 microg rgp160 every 3 months for 3 years
Number of subjects: 835

Group type: COMPARATOR
Intervention: Placebo (alum adjuvant alone)
Number of subjects: 835
Study: 7564328

Group type: EXPERIMENTAL
Intervention: 40 mg Ro 40‐5967 in 60 min
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 40 mg Ro 40‐5967 in 30 min
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 40 mg Ro 40‐5967 in 15 min
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 80 mg Ro 40‐5967 in 30 min (two simultaneous doses of 40 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 80 mg Ro 40‐5967 in 30 min (one arm)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 1682645

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa octavalent O‐polysaccharide‐toxin A conjugate vaccine
Number of subjects: 22